← All trials
NCT06578572
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 30, 2024
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2025
- First posted
- Aug 29, 2024
- Last posted
- Aug 29, 2024
- Enrollment
- 16200
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of LondonLead sponsor
- National Malaria Control Programme, The GambiaCollaborator
- Institute Tropical Medicine Belgium and MRC Unit in The GambiaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.